These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 14663603)

  • 1. [Lipoprotein(a): Aspects of pathophysiology, epidemiology and treatment].
    Thomas HP; Steinhagen-Thiessen E
    Z Kardiol; 2003; 92(Suppl 3):III53-8. PubMed ID: 14663603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy].
    Seidel D
    Z Kardiol; 2003; 92(Suppl 3):III6-27. PubMed ID: 14663597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Heparin-induced extracorporeal LDL precipitation (H.E.L.P.)].
    Horstkotte D; Mellwig KP
    Z Kardiol; 2003; 92(Suppl 3):III1-5. PubMed ID: 14663596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical long-term results of H.E.L.P.-apheresis].
    Schuff-Werner P
    Z Kardiol; 2003; 92(Suppl 3):III28-9. PubMed ID: 14663598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis.
    Bosch T; Lennertz A; Schenzle D; Dräger J;
    J Clin Apher; 2002; 17(4):161-9. PubMed ID: 12494408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetics and metabolism of lipoprotein(a) and their clinical implications (Part 1).
    Dieplinger H; Kronenberg F
    Wien Klin Wochenschr; 1999 Jan; 111(1):5-20. PubMed ID: 10067265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin-mediated extracorporeal low-density lipoprotein precipitation: rationale for a specific adjuvant therapy in cardiovascular disease.
    Blessing F; Wang Y; Walli AK; Seidel D
    Transfus Apher Sci; 2004 Jun; 30(3):255-66. PubMed ID: 15172631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [H.E.L.P. apheresis and oxidative stress].
    Pulawski E; Mellwig KP; Horstkotte D
    Z Kardiol; 2003; 92(Suppl 3):III38-41. PubMed ID: 14663600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of DALI LDL-apheresis at high blood flow rates: a prospective multicenter study.
    Wendler T; Schilling R; Lennertz A; Sodemann K; Kleophas W; Messner H; Riechers G; Wagner J; Keller C; Bosch T
    J Clin Apher; 2003; 18(4):157-66. PubMed ID: 14699591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lipoprotein(a): risk factor for atherosclerotic vascular disease important to take into account in practice].
    Couderc R; Maachi M
    Ann Biol Clin (Paris); 1999; 57(2):157-67. PubMed ID: 10210742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Myocardial perfusion under H.E.L.P. -apheresis. Objectification by PET].
    Mellwig KP; Baller D; Schmidt HK; V Buuren F; Wielepp JP; Burchert W; Horstkotte D
    Z Kardiol; 2003; 92(Suppl 3):III30-7. PubMed ID: 14663599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein(a): from molecules to therapeutics.
    Bermúdez V; Arráiz N; Aparicio D; Rojas E; Gotera D; Guerra X; Canelón R; Faría J; Sorell L; Amell A; Reyna N; Cabrera M; Mengual E; Cano R; Cano C; Velasco M
    Am J Ther; 2010; 17(3):263-73. PubMed ID: 20479580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-Induced extracorporeal low-density lipoprotein precipitation apheresis: a new therapeutic concept in the treatment of sudden hearing loss.
    Suckfüll M
    Ther Apher; 2001 Oct; 5(5):377-83. PubMed ID: 11778923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease.
    Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):8-13. PubMed ID: 25672934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein(a): a unique risk factor for cardiovascular disease.
    Anuurad E; Boffa MB; Koschinsky ML; Berglund L
    Clin Lab Med; 2006 Dec; 26(4):751-72. PubMed ID: 17110238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
    Schampera S; Fischer S; Weiss N; Julius U
    Atheroscler Suppl; 2015 May; 18():209-14. PubMed ID: 25936328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of sudden hearing loss through Fibrinogen/LDL-apheresis. A prospective, randomized multicenter trial].
    Suckfüll M; Seidel D; Thiery J; Mazurek B; Jaehne M; Gronemeyer J; Reichel O; Sasama J; Kichigina S; Möller M; Beil FU; Schrameyer-Wernecke A; Kassner U; Koch M; Jaeger B; Osterkorn K; Osterkorn D
    Z Kardiol; 2003; 92(Suppl 3):III59-63. PubMed ID: 14663604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study.
    Klingel R; Heibges A; Fassbender C
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):46-50. PubMed ID: 25644612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three different LDL apheresis columns efficiently and equally reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles.
    Hovland A; Marcovina S; Hardersen R; Enebakk T; Mollnes TE; Lappegård KT
    Transfus Apher Sci; 2012 Feb; 46(1):73-6. PubMed ID: 22206792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.
    Schmitz G; Orsó E
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):21-5. PubMed ID: 25708587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.